What is Lymphangioleiomyomatosis

Lymphangioleiomyomatosis (LAM) is a rare and progressive lung disease that primarily affects women of childbearing age. It is characterized by the abnormal growth of smooth muscle cells, called LAM cells, in the lungs, lymph nodes, and other organs.

LAM can lead to the formation of cysts in the lungs, causing breathing difficulties, recurrent lung collapses, and reduced lung function. Symptoms may include shortness of breath, coughing, chest pain, and fatigue.

The exact cause of LAM is not fully understood, but it is believed to be related to genetic mutations. LAM can occur sporadically or in association with a rare genetic disorder called tuberous sclerosis complex (TSC).

Diagnosis of LAM involves a combination of clinical evaluation, lung function tests, imaging studies (such as CT scans), and sometimes a lung biopsy. While there is currently no cure for LAM, treatment options aim to manage symptoms and slow disease progression.

Research and advancements in understanding LAM have led to the development of targeted therapies that can help stabilize lung function and improve quality of life for patients. Regular monitoring and individualized treatment plans are crucial in managing this complex disease.